Executive Vice President and Chief Operating Officer
Stuart Arbuckle

Stuart A. Arbuckle

Executive Vice President and Chief Operating Officer
Stuart Arbuckle

Stuart joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Operating Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which includes activities that support the approved use of Vertex’s marketed medicines around the world. He also leads the program and portfolio management, commercial manufacturing, supply chain, human resources, and corporate communications functions.

He graduated with a degree in pharmacology and physiology from the University of Leeds in the United Kingdom, and prior to Vertex, he held multiple leadership roles at Amgen and GlaxoSmithKline (GSK) plc.  

Stuart serves on the board of directors for Rhythm Pharmaceuticals and ImmunoGen, as a national board member of the Cancer Support Community, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.

Stuart joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Operating Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which includes activities that support the approved use of Vertex’s marketed medicines around the world. He also leads the program and portfolio management, commercial manufacturing, supply chain, human resources, and corporate communications functions.

He graduated with a degree in pharmacology and physiology from the University of Leeds in the United Kingdom, and prior to Vertex, he held multiple leadership roles at Amgen and GlaxoSmithKline (GSK) plc.  

Stuart serves on the board of directors for Rhythm Pharmaceuticals and ImmunoGen, as a national board member of the Cancer Support Community, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.